Necator americanus L3 larvae

PreclinicalBiologic

Necator americanus L3 larvae is one of 2 biologic programs targeting Hookworm Infection. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hookworm InfectionNot yet recruiting

Hookworm InfectionPreclinical

Not yet recruiting

Competition

Competitive Landscape

1 competitor in Hookworm Infection

#DrugCompanyPhaseTrials

Na-ASP-2 Hookworm Vaccine

AAlbert B. Sabin Vaccine Institute

Preclinical

1 2

Necator americanus L3 larvae

LLeiden University Medical Center

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

N/ANot yet recruiting

Hookworm Infection

NCT06478498

Clinical

Trials by Indication[1]

Hookworm Infection2 trials

Establishing a Controlled Human Hookworm Infection Model at Leiden University Medical Center

Completed·LLeiden University Medical Center·N/A·NCT03126552·4 enrolled

Immune Responses in the Skin After Hookworm Infection

Not yet recruiting·LLeiden University Medical Center·N/A·NCT06478498·5 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Necator americanus L3 larvae. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Necator americanus L3 larvae compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Necator americanus L3 larvae. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Leiden University Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: LLeiden University Medical Center

Necator americanus L3 larvae

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Hookworm Infection2 trials

References

Drug Info

Quick Facts

Related News